64 citations
,
June 1995 in “Steroids” Inhibitors of the enzyme 5 alpha-reductase could potentially treat disorders like prostate cancer and baldness.
54 citations
,
November 1995 in “The Journal of Clinical Endocrinology & Metabolism” Females with 5 alpha-reductase-2 deficiency have less body hair, no acne, normal fertility, and delayed menarche.
36 citations
,
October 2009 in “Journal of Investigative Dermatology” Dihydrotestosterone can be made from dehydroepiandrosterone in skin cells without needing testosterone.
31 citations
,
January 1995 in “The American journal of medicine” Testosterone and dihydrotestosterone play a role in women's health issues like excess hair and baldness, and treatments blocking these hormones may help.
22 citations
,
September 1994 in “The Journal of Clinical Endocrinology and Metabolism” Finasteride reduces dihydrotestosterone, increases testosterone, and may treat hirsutism in women.
8 citations
,
May 2020 in “Arthritis research & therapy” DHT inhibition may increase spinal bone growth in ankylosing spondylitis.
1 citations
,
January 2002 in “PubMed” PM-9, like finasteride, may help treat certain diseases by blocking a key enzyme.
57 citations
,
January 1986 in “The Prostate” The document suggests that targeting the hormone DHT could be a more effective treatment for prostate cancer than targeting testosterone.
50 citations
,
February 2013 in “Annals of Clinical Biochemistry” Understanding how DHT works is important for diagnosing and treating hormone-related disorders.
31 citations
,
September 2008 in “International Journal of Andrology” 5-alpha-reductase inhibitors may cause a low incidence of erectile dysfunction that decreases over time.
June 2023 in “Journal of personalized medicine” Androgen treatment with dihydrotestosterone may help maintain height in patients with 5-α-reductase type 2 deficiency, especially before puberty.
February 2021 in “International Journal of Science and Research (IJSR)” A higher testosterone/dihydrotestosterone ratio in PCOS patients may indicate worse metabolic health.
Dihydrotestosterone (DHT) and its active metabolites play a key role in various diseases, and the development of 5α-reductase inhibitors can help treat these conditions.
218 citations
,
December 2011 in “Advances in Urology” The document concludes that the 5 alpha-reductase enzymes are important in steroid metabolism and related to various human diseases, with inhibitors used to treat conditions like male pattern baldness and prostate issues.
124 citations
,
March 2012 in “JAMA” Testosterone's muscle-building effects do not require its conversion to DHT.
124 citations
,
September 1992 in “Endocrinology” The human type II 5α-reductase gene, linked to certain male health conditions, has a specific structure and low similarity to other related genes.
115 citations
,
March 2001 in “Baillière's best practice and research in clinical endocrinology and metabolism/Baillière's best practice & research. Clinical endocrinology & metabolism” Key enzymes control androgen levels, affecting hormone activity and potential treatments.
101 citations
,
April 1994 in “Baillière's clinical endocrinology and metabolism” 5α-reductase is essential for male sexual development and its inhibitors have potential in treating various conditions related to hormone action.
89 citations
,
February 1993 in “Journal of Medicinal Chemistry” New compounds called benzoquinolinones may treat conditions linked to excess DHT.
78 citations
,
December 2008 in “The Journal of Sexual Medicine” 5-alpha reductase inhibitors can cause sexual side effects like erectile dysfunction, but the exact reasons are unclear.
73 citations
,
January 1994 in “European Urology” Finasteride works better than Permixon in reducing dihydrotestosterone levels.
70 citations
,
June 1993 in “Biochemistry” Finasteride slowly binds to 5-alpha-reductase, affecting enzyme stability and inhibitor potency.
57 citations
,
February 1983 in “The Journal of clinical endocrinology and metabolism/Journal of clinical endocrinology & metabolism” Dihydrotestosterone increases the activity of an enzyme in pubic skin cells that converts testosterone to dihydrotestosterone.
53 citations
,
June 1993 in “Proceedings of the National Academy of Sciences of the United States of America” LY191704 is a compound that effectively blocks a specific enzyme involved in hormone conversion and could help treat enlarged prostate and hair loss.
53 citations
,
January 1986 in “Endocrinology” Blocking a specific enzyme in male rat fetuses leads to the development of nipples and feminized genitalia.
51 citations
,
July 2013 in “Brain Research” Testosterone needs to be converted to DHT to reduce stress response in male rats.
50 citations
,
August 1985 in “Journal of steroid biochemistry/Journal of Steroid Biochemistry” Spironolactone reduces the enzyme activity that converts testosterone to DHT, helping treat excessive hair growth in women.
49 citations
,
January 2004 in “Journal of steroid biochemistry and molecular biology/The Journal of steroid biochemistry and molecular biology” Selective non-steroidal inhibitors of 5α-reductase type 1 can help treat DHT-related disorders.
47 citations
,
January 2003 in “Current opinion in urology” A new drug, dutasteride, is at least as effective as the older drug, finasteride, for treating enlarged prostate and may have additional uses.
38 citations
,
October 2014 in “Current Opinion in Endocrinology, Diabetes and Obesity” 5-alpha reductase deficiency leads to male sexual development issues and treatments like finasteride help with prostate enlargement and hair loss.